Unlocking The Potential of CCT6-3P: A Protein Involved in Multiple Tissues
Unlocking The Potential of CCT6-3P: A Protein Involved in Multiple Tissues
CCT6-3P, also known as CCT6-3 protein, is a protein that is expressed in various tissues of the body, including the brain, heart, and blood vessels. It is a member of the CCT6 family, which is characterized by the presence of a variable region of the protein that is responsible for its unique structure and function.
One of the unique features of CCT6-3P is its ability to interact with other proteins, particularly those that are involved in the formation of blood vessels. This interaction is important for the regulation of blood flow and the development of various diseases, including heart disease and cancer.
In addition to its role in blood vessel formation, CCT6-3P has also been shown to play a key role in the regulation of cell growth and differentiation. This is important because many diseases, including cancer, are characterized by the uncontrolled growth and proliferation of cells.
The research on CCT6-3P is still in its early stages, but it has the potential to be a drug target or biomarker for a variety of diseases. This is because its interactions with other proteins make it a promising target for small molecules that can be used to treat a range of conditions, including heart disease, cancer, and neurological disorders.
One of the key challenges in studying CCT6-3P is its complex structure. The protein is composed of several domains, including an N-terminus, a transmembrane region, and a C-terminus. The N-terminus is the region that interacts with other proteins, while the C-terminus is the region that interacts with the extracellular matrix.
The transmembrane region is the region that lies between the N-terminus and the C-terminus, and it is responsible for the regulation of the protein's activity. This region has been shown to contain several unique features that are involved in its regulation.
One of the key features of the transmembrane region is the presence of a unique protein called Trp-22. Trp-22 is a glycophosphorylated protein that is involved in the regulation of several cellular processes, including cell signaling, protein synthesis, andvascular remodeling.
Another unique feature of the transmembrane region is the presence of a protein called Myc-21. Myc-21 is a transcription factor that is involved in the regulation of gene expression, and it is highly expressed in the brain and other tissues.
The C-terminus of CCT6-3P is the region that interacts with the extracellular matrix, and it is responsible for the regulation of the protein's activity in this region. This region has been shown to contain several unique features that are involved in its regulation.
One of the key features of the C-terminus is the presence of a protein called FBN1. FBN1 is a protein that is involved in the regulation of blood clotting, and it is highly expressed in the blood vessels.
Another unique feature of the C-terminus is the presence of a protein called PDGF2. PDGF2 is a protein that is involved in the regulation of cell growth and differentiation, and it is highly expressed in tissues of the brain, including the brain.
In conclusion, CCT6-3P is a protein that is expressed in various tissues of the body and is involved in the regulation of blood vessel formation, cell growth and differentiation, and blood clotting. Its unique structure and interactions with other proteins make it a promising target for small molecules that can be used to treat a range of conditions. Further research is needed to fully understand the role of CCT6-3P in the regulation of these processes and to develop effective treatments for
Protein Name: Chaperonin Containing TCP1 Subunit 6 Pseudogene 3
The "CCT6P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCT6P3 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A
